Overview of Arrowhead Pharmaceuticals - Arrowhead Pharmaceuticals has made significant recent progress and accomplishments, particularly highlighted by the update on the Sarepta partnership [2] Future Expectations - Investors should anticipate further developments from Arrowhead as the company approaches the end of the year and into 2026 [2]

MLTX DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - MLTXNovember 27, 2025 6:12 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - November 27, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive ...

One clinical-stage biotech is defying gravity—here’s why its record-breaking run is catching institutional attention.New York City-based Apis Capital Advisors disclosed a new position in Celcuity Inc. (CELC +1.28%), acquiring 776,000 shares valued at $38,334,400 as of September 30, according to an SEC filing submitted on November 14, 2025.What HappenedAccording to a Securities and Exchange Commission (SEC) filing dated November 14, Apis Capital Advisors, LLC initiated a new position in Celcuity (CELC +1.28% ...

SAN FRANCISCO, Nov. 27, 2025 (GLOBE NEWSWIRE) -- Global plaintiffs’ rights law firm Hagens Berman reminds investors of the December 8, 2025, deadline to move the Court for appointment as lead plaintiff in the securities class action lawsuit filed against aTyr Pharma, Inc. (NASDAQ: ATYR). The litigation follows a catastrophic 83% single-day stock collapse after the company’s flagship drug trial failed to meet its primary endpoint. The lawsuit alleges that aTyr and its executives provided materially false and ...

Key Takeaways IRWD's growth is driven by its U.S. Linzess partnership with ABBV, which posted robust Q3 resultsStronger Linzess demand led IRWD to lift its 2025 revenue outlook following a solid Q3 performance.PBYI's Nerlynx posted $144.2M sales in the first nine months of 2025, up 2.5% year over year.Both Ironwood Pharmaceuticals (IRWD) and Puma Biotechnology (PBYI) are small biotechs, concentrating on the successful commercialization of their respective products with the goal of establishing leadership in ...

Applied Therapeutics Inc. (APLT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the ...

Accessibility StatementSkip Navigation NEW YORK, Nov. 27, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline. So what: If you purchased MoonLake common stock during the Class Period you may be entitled to compensation without payment of any out of pocket ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Skye Bioscience, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the Skye Bioscience securities is from November 4, 2024, to October 3, 2025, inclusive [1]. - Investors who purchased Skye securities during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 16, 2026 [2]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions [3]. - Rosen Law Firm has a history of significant settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions for investors [3]. - The firm has been consistently ranked among the top firms for securities class action settlements since 2013 [3]. Group 3: Case Allegations - The lawsuit alleges that during the Class Period, defendants made materially false and misleading statements regarding Skye's business and the effectiveness of its product, nimacimab [4]. - Specifically, it is claimed that nimacimab was less effective than represented, leading to overstated clinical, regulatory, and commercial prospects [4]. - The lawsuit asserts that when the true information became public, investors suffered damages as a result [4].

Key Takeaways BEAM and NTLA are compared as gene editing biotechs with pipelines at different development stages.BEAM advances multiple SCD programs and updates its BEAM-101 and BEAM-301 studies across phases.NTLA pushes late-stage in vivo candidates while a clinical hold on nex-z raises safety concerns.Beam Therapeutics (BEAM) and Intellia Therapeutics (NTLA) are clinical-stage companies developing investigational gene therapies. While BEAM’s pipeline candidates are still in early-stage development, NTLA i ...

Core Insights - Halozyme Therapeutics, Inc. (NASDAQ:HALO) is recognized as one of the best small-cap stocks with significant upside potential according to Reddit discussions [2] - The company focuses on oncology therapies targeting the tumor microenvironment and has recently acquired Elektrofi to enhance its drug delivery capabilities [2] - The stock has appreciated approximately 54% year-to-date [2] Financial Performance - Halozyme reported a revenue growth of 22% year-over-year in its latest quarterly results, with royalty revenue increasing by 52% [3] - The company raised its full-year guidance in May, indicating strong earnings performance [4] Product Developments - The FDA approved Darzalex Faspro, an injectable version of the multiple myeloma therapy daratumumab, developed by Johnson & Johnson and Halozyme, as a front-line treatment for light chain amyloidosis [3] Market Sentiment - Artisan Small Cap Fund noted that despite strong earnings and raised guidance, Halozyme's shares faced pressure due to uncertainty regarding new draft guidance from the Centers for Medicare and Medicaid Services (CMS) on drug pricing [4] - The fund expressed a belief that while Halozyme has investment potential, some AI stocks may offer greater returns with limited downside risk [4]